Modern management of acne

Victoria Rebecca Harris and Alan J Cooper
Med J Aust 2017; 206 (1): . || doi: 10.5694/mja16.00516
Published online: 16 January 2017


  • Acne is a chronic inflammatory disease of the pilosebaceous unit resulting from androgen-induced increased sebum production; altered keratinisation; bacterial colonisation of hair follicles on the face, neck, chest and back by Propionibacterium acnes; and an inflammatory response in the skin. The exact way these processes interact and the order in which they occur in the pathogenesis of acne are still unclear.
  • Scarring that occurs from acne, particularly severe acne, can persist a lifetime and have long lasting psychosocial effects. Depression, social isolation and suicidal ideation are frequent comorbidities in acne.
  • Despite the plethora of topical and systemic treatments available for acne, there is a relative lack of quality evidence for its application. Of the systemic treatments available, oral isotretinoin remains the most effective well established treatment for acne that targets all the aetiological factors.
  • Current guidelines for the treatment of acne are based largely on expert consensus and advocate a combination of topical agents in mild to moderate cases and reserve the use of systemic therapies for moderate to severe or refractory cases of acne. However, given the psychosocial impacts of acne, there is a strong argument for early, effective treatment with systemic therapy when topical and general measures have failed.

  • Royal North Shore Hospital, Sydney, NSW


Competing interests:

Alan Cooper was a member of the Roaccutane Advisory Board, a group of Australian dermatologists brought together by Roche Products Pty Ltd. The preparation of this document was not supported in any way by Roche Products Pty Ltd.

  • 1. Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol 2015; 172 Suppl 1: 3-12.
  • 2. Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008; 58: 56-59.
  • 3. Dreno B, Thioboutot D, Layton AM, et al. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol 2015; 29: 1096-1106.
  • 4. Spencer EH, Ferdowsian HR, Barnard ND. Diet and acne: a review of the evidence. Int J Dermatol 2009; 48: 339-347.
  • 5. Davidovic BB, Wold R. The role of diet in acne: facts and controversies. Clin Dermatol 2010; 28: 12-16.
  • 6. Adebamowo CA, Spiegelman D, Danby FW, et al. Milk consumption and acne in teenage boys. J Am Acad Dermatol 2008; 58: 787-793.
  • 7. Smith RN, Mann NJ, Braue A, et al. A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. Am J Clin Nutr 2007; 86: 107-115.
  • 8. Dreno B, Poli F. Epidemiology of acne. Dermatology 2003; 206: 7-10.
  • 9. Bastille V, Snieder H, MacGregor AJ, et al. The influence of genetics and environmental factors in the pathogenesis of can: a twin study of acne in women. J Invest Dermatol 2002; 119: 317-322.
  • 10. Navarini AA, Simpson MA, Weale M, et al. Genome-wide association study identifies three novel susceptibility loci for severe acne vulgaris. Nat Commun 2014; 5: 4020.
  • 11. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74: 945-973.
  • 12. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet 2012; 379: 361-372.
  • 13. Zouboulis C. Acne and sebaceous gland function. Clin Dermatol 2004; 22: 360-366.
  • 14. Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic quality of life questionnaires. Br J Dermatol 1999; 140: 672-676.
  • 15. Gieler U. Acne and Quality of Life – impact and management. J Eur Acad Dermatol Venereol 2015; 29 Suppl 4: 12-14.
  • 16. Thiboutot D, Gollnick H, Bettoli V, et al. New Insights into the management of acne: an update from the global alliance to improve outcomes in acne group. J Am Acad Dermatol 2009; 60 Suppl 5: S1-S37.
  • 17. Suh DH, Kwon HH. What’s new in the physiology of acne? Br J Dermatol 2015; 172 Suppl 1: 13-19.
  • 18. Walker J, Adams B. Cutaneous manifestations of anabolic- androgenic steroid use in athletes. Int J Dermatol 2009; 48: 1044-1048.
  • 19. Gollnick HPM. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol 2015; 29 Suppl 5: 1-7.
  • 20. Gollnick H, Cunliff W, Berson D, et al. Management of acne: a report from global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003; 49 Suppl 1: S1-S37.
  • 21. Nast A, Dreno B, Bettoli V, et al. European evidence based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012; 26 Suppl 1: 1-29.
  • 22. Barratt H, Hamilton F, Car J, et al. Outcome measures in acne vulgaris: systematic review. Br J Dermatol 2009; 160: 132-136.
  • 23. Tan JK, Tang J, Gupta AK, et al. Development and validation of a comprehensive acne severity scale. J Cutan Med Surg 2007; 11: 211-216.
  • 24. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
  • 25. Gollnick HPM, Dreno B. Pathophysiology and management of acne. J Eur Acad Dermatol Venereol 2015; 29 Suppl 4: 1-2.
  • 26. eTG complete [website]. Melbourne: Therapeutic Guidelines Limited; 2016. (accessed Apr 2016).
  • 27. Latriano L, Tzimas G, Wong F, et al. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolite after single doses or long term use. J Am Acad Dermatol 1997; 36(3 Pt 2): S37-S46.
  • 28. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet 1993; 341: 1181-1182.
  • 29. Tan J, Humphrey S, Vender R, et al. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol 2014; 171: 1508-1516.
  • 30. Shaughnessy KK, Bouchard SM, Mohr MR, et al. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol 2010; 62: 315-318.
  • 31. Goulden V, Glass D, Cunliff WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996; 134: 693-695.
  • 32. Glassman AH, Bigger T. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-1782.
  • 33. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003; 4: 813-831.
  • 34. Arowojolu AO, Gallo MF, Lopez L M, et al. Cochrane Review: combined oral contraceptive pills for treatment of acne. Evid-Based Child Health 2011; 6: 1340-1433.
  • 35. Shaw J. Low dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000; 43: 498-502.
  • 36. Sato K, Matsumoto D, Iiuka F, et al. Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians. Aesthetic Plast Surg 2006; 30: 689-694.
  • 37. Shaw JC, White LE. Long-term safety of spironolactone in acne: results of an 8-year follow up study. J Cutan Med Surg 2002; 6: 541-545.
  • 38. Cunliff WJ, Hughes BR, Layton AM, et al. Retinoids today and tomorrow. The isotretinoin mechanism of action. In: Proceedings of the Satellite Symposium to the First Congress of the European Academy of Dermatology and Venereology (EAVD). Florence: Roche, 1989: 5-13.
  • 39. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10: 490-496.
  • 40. Webster G. Acne vulgaris. BMJ 2002; 325: 475-479.
  • 41. Blasiak R. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol December 2013; 149: 1392-1397.
  • 42. Amichai B, Semer A, Grunwald MH. Low dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54: 644-646.
  • 43. Cooper A. Treatment of acne with oral isotretinoin: recommendations based on Australian experience. Australas J Dermatol 2003; 44: 97-105.
  • 44. Bérard A, Laurent A, Gideon K, et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63: 196-205.
  • 45. Sundström A, Alfredsson L, Sjölin-Forsberg G, et al. Association of suicide attempts with acne and acne treatment with isotretinoin: retrospective Swedish cohort study. BMJ 2010; 341: c5812.
  • 46. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression, and isotretinoin: is there a causal link? J Am Acad Dermatol 2001; 45: S168-S175.
  • 47. Rubinow D, Peck G, Squillace K, et al. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987; 17: 25-32.
  • 48. Gieler U, Gieler T, Kupfer JP. Acne and quality of life - impact and management. J Eur Acad Dermatol Venereol 2015; 29 Suppl 4: 12-14.
  • 49. Kessler E, Flanagan K, Chia C, et al. Comparison of α- and β-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatol Surg 2008; 34: 45-51.
  • 50. Lee HS, Kim IH. Salicylic acid peels for the treatment of acne vulgaris in Asian patients. Dermatol Surg: 2003; 29: 1196-1199.
  • 51. Lee W, Shalita A, Poh-Fitzpatrick M. Comparative studies of porphyrin production in Propionibacterium acne and Propionibacterium granulosum. J Bacteriol 1978; 133: 811-815.
  • 52. Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in treatment of acne vulgaris. Br J Dermatol 2000; 142: 973-978.
  • 53. Taub AF. Procedural treatments for acne vulgaris. Dermatol Surg 2007; 33: 1005-1026.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.